Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma

Eric Van den Neste, Marc André, Thomas Gastinne, Aspasia Stamatoullas, Corinne Haioun, Amine Belhabri, Oumedaly Reman, Olivier Casasnovas, Hervé Guesquieres, Gregor Verhoef, Marie-José Claessen, Hélène A. Poirel, Marie-Christine Copin, Romain Dubois, Peter Vandenberghe, Ioanna-Andrea Stoian, Anne S. Cottereau, Sarah Bailly, Laurent Knoops, and Franck Morschhauser

Disclosures: E. Van Den Neste: Roche, Janssen, Abbvie: travel grants; Celgene, Servier: consultancy Marc André: Novartis: advisory board Aspasia Stamatoullas: Takeda, Celgene: consultancy The other authors declare no conflict of interest.

Contributions: EV, MA, GV, PV, LK and FM contributed to study design and concept. EV and FM were responsible for the conduct of the study. HP and LK performed the central laboratory analyses. EV, MA, TG, AS, CH, AB, OR, OC, HG, GV, MJC, SB, MCC, RD and FM supported the study. EV and FM contributed to data analyses and drafted the report. All authors reviewed the manuscript and approved its final version.